piperidine/비만증

FIELD OF THE INVENTION The present invention relates to Bicyclic Piperidine and piperazine Derivatives, compositions comprising a Bicyclic Piperidine and piperazine Derivative, and methods of using the Bicyclic Piperidine and piperazine Derivatives for treating or preventing obesity, diabetes, a

FIELD OF THE INVENTION This invention relates to antagonists for melanin-concentrating hormone (MCH) and their use in the treatment of metabolic and eating disorders. It generally discloses novel compounds having MCH receptor modulatory activity, pharmaceutical compositions containing one or more

FIELD OF THE INVENTION This invention relates to antagonists for melanin-concentrating hormone (MCH) and their use in the treatment of metabolic and eating disorders, novel compounds having MCH receptor modulatory activity, pharmaceutical compositions containing one or more such modulators, methods

FIELD OF THE INVENTION This invention relates to antagonists of melanin-concentrating hormone (MCH) and their use in the treatment of obesity, eating disorders and diabetes, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds. BACKGROUND OF THE

FIELD OF THE INVENTION This invention relates to antagonists for melanin-concentrating hormone (MCH) and their use in the treatment of metabolic and eating disorders, novel compounds having MCH receptor modulatory activity, pharmaceutical compositions containing one or more such modulators, methods

TECHNICAL FIELD The present invention relates to a piperidine derivative. More specifically, the present invention relates to (1) a piperidine derivative of formula (I) ##STR00002## (2) a method for the preparation thereof, (3) a composition comprising it as an active ingredient, (4) a compound of

FIELD OF THE INVENTION This invention relates to new compounds, in particular piperidine derivatives, to processes for preparing such compounds, to their use as inhibitors of acetyl-CoA carboxylase(s), to methods for their therapeutic use, in particular in diseases and conditions mediated by the

FIELD OF THE INVENTION The present invention relates to Bridged Bicyclic Piperidine Derivatives, compositions comprising a Bridged Bicyclic Piperidine Derivative, and methods of using the Bridged Bicyclic Piperidine Derivatives for treating or preventing obesity, diabetes, a diabetic complication, a

The present invention is concerned with novel N-aryl piperidine substituted biphenylcarboxamide compounds having apolipoprotein B inhibiting activity and concomitant lipid lowering activity. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a national phase application under 35 U.S.C. .sctn. 371 of International Application No. PCT/KR2015/009944 filed Sep. 22, 2015, which claims priority to Korean Patent Application No. 10-2014-0126959 filed Sep. 23, 2014. The contents of each

FIELD OF THE INVENTION The present invention relates to piperidine derivatives, their synthesis, and their use as melanocortin receptor (MC-R) agonists. More particularly, the compounds of the present invention are selective agonists of the melanocortin-4 receptor (MC-4R) and are thereby useful for

SUMMARY OF THE INVENTION The present invention relates to piperidine derivatives, their synthesis, and their use as melanocortin receptor (MC-R) agonists. More particularly, the compounds of the present invention are selective agonists of the melanocortin-4 receptor (MC-4R) and are thereby useful

FIELD OF THE INVENTION The present invention relates generally to the fields of medicinal chemistry and, more specifically, to novel compounds and their use as anti-obesity agents. BACKGROUND OF THE INVENTION Obesity, defined as an excess of body fat relative to lean body mass, contributes to and

FIELD OF THE INVENTION The present invention relates to piperidine derivatives, their synthesis, and their use as melanocortin receptor (MC-R) agonists. More particularly, the compounds of the present invention are selective agonists of the melanocortin-4 receptor (MC-4R) and are thereby useful for

FIELD OF THE INVENTION The present invention relates to bridged piperidine derivatives, their synthesis, and their use as melanocortin receptor (MC-R) agonists. More particularly, the compounds of the present invention are selective agonists of the melanocortin-4 receptor (MC-4R) and are thereby